Caribou Biosciences (CRBU) Capital Expenditures (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Capital Expenditures of -$216000.0 for Q4 2025, down 104.79% year-over-year from $4.5 million in Q4 2024, and down 114.32% quarter-over-quarter from $1.5 million in Q3 2025.
Caribou Biosciences (CRBU) Capital Expenditures (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Capital Expenditures for 6 consecutive years, with -$216000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures fell 104.79% year-over-year to -$216000.0; the TTM figure through Mar 2026 stood at $317000.0 (down 92.91% YoY), while the FY2025 annual figure was $1.4 million, down 72.15% from the prior year.
- Capital Expenditures retreated to -$216000.0 in Q4 2025 per CRBU's latest filing, from $1.5 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.8 million in Q3 2023 and bottomed at -$3.5 million in Q4 2022.
- Historically, Capital Expenditures has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
- Annual changes were most pronounced in 2021 — Capital Expenditures sank 1800.0% — and 2022, when it jumped 3186.36%.
- Caribou Biosciences' Capital Expenditures stood at $1.9 million in 2021, then tumbled by 287.48% to -$3.5 million in 2022, then surged by 165.54% to $2.3 million in 2023, then soared by 97.94% to $4.5 million in 2024, then slumped by 104.79% to -$216000.0 in 2025.
- Business Quant data shows CRBU's Capital Expenditures at -$216000.0 in Q4 2025, $1.5 million in Q3 2025, and -$975000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | 72,000.00 |
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | -216,000.00 |
| Dec 31, 2025 | -216,000.00 |
| Sep 30, 2025 | 1.51 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | -975,000.00 |
| Jun 30, 2025 | -975,000.00 |
| Mar 31, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 198,000.00 |
| Sep 30, 2024 | 198,000.00 |
| Jun 30, 2024 | -1.27 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.45 Mn |